Asston Pharmaceuticals Limited announced its Board of Directors has approved the allotment of 24,10,431 equity shares. These shares, with a face value of ₹10 each, were issued at a premium of ₹115 per share, totaling ₹115 per share. This move increases the company’s paid-up equity share capital to approximately ₹10.92 crore, comprising over 1.09 crore equity shares. The newly allotted shares will rank pari passu with existing shares.
Significant Equity Allotment Approved
Asston Pharmaceuticals Limited has successfully concluded a Board Meeting, at which its Directors gave the go-ahead for the allotment of 24,10,431 equity shares. These shares were issued at a price of ₹115 each, incorporating a premium of ₹105 per share over the face value of ₹10.
Impact on Share Capital
Following this allotment, the paid-up equity share capital of Asston Pharmaceuticals has grown to approximately ₹10,92,27,910. This increase is represented by 1,09,22,791 equity shares, each with a face value of ₹10. The newly issued equity shares will hold the same rights and privileges as the existing shares, ranking pari passu in all respects.
Preferential Allotment Details
The issuance was conducted as a preferential allotment. The total number of investors participating in this allotment stands at 15. Key allottees include Vijay Rathee, who received 13,17,391 shares, and Vijaylaxmi Infra Projects Private Limited, allocated 7,82,608 shares. Several other individuals and entities received allotments ranging from 5,217 to 21,739 shares.
Board Meeting Concluded
The Board Meeting where this significant decision was made commenced at 10:30 A.M. and concluded at 10:45 A.M. on September 5, 2026.
Source: BSE
